Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06291987
Title	Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation (MPN)
Acronym	MPN
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	University of Chicago
Indications	essential thrombocythemia myeloproliferative neoplasm polycythemia vera chronic myeloid leukemia myelofibrosis myelodysplastic/myeloproliferative neoplasm myelodysplastic syndrome
Therapies	Ivosidenib + Ruxolitinib
Age Groups:	senior \| adult
Covered Countries	USA